Pathogenesis and clinical features―recent progress in research:essential thrombocythemia Yoshitaka Miyakawa 1 1Division of Hematology, Department of Internal Medicine, Keio University School of Medicine Keyword: 本態性血小板血症(ET) , JAK2 , V617F変異 pp.255-259
Published Date 2010/3/15
DOI https://doi.org/10.11477/mf.1542102251
  • Abstract
  • Look Inside
  • Reference

The discovery of JAK2 V617F and thrombopoietin receptor(MPL)W515L/K mutations in myeloproliferative neoplasms was reported in 2005. WHO newly adopted these genetic markers into the updated diagnostic criteria of myeloproliferative neoplasms such as polycythemia vera, essential thrombocythemia and myelofibrosis. These mutations induce the constitutive activation of JAK2 in the hematopoietic stem cells followed by proliferation of megakaryocytes and increase of platelets in essential thrombocythemia.

Copyright © 2010, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1367 印刷版ISSN 0485-1420 医学書院